Outcomes of Haploidentical Transplants with PT-CY versus 10/10 MUD Transplants with ATG in Germany.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
05 Oct 2024
Historique:
accepted: 22 09 2024
received: 20 05 2024
revised: 19 09 2024
medline: 6 10 2024
pubmed: 6 10 2024
entrez: 5 10 2024
Statut: aheadofprint

Résumé

Allogeneic stem cell transplantation (alloHSCT) is the best curative treatment modality for many malignant haematological disorders. In the absence of a matched related donor (MRD), matched unrelated donors (MUD) and haploidentical donors (Haplo-Tx) are the most important sources of stem cells. However, multicenter real-life data which compare 10/10 MUD transplantations with Haplo-Tx is still limited. In this registry based retrospective study, we compared the outcomes of alloHSCTs from 10/10 MUD with anti-thymocyte globulin (ATG) based regimens (n=7050) versus Haplo-Tx using post-transplant cyclophosphamide (PT-CY Haplo) (n=487) in adult patients with haematological malignancies between 2010 and 2020. Cox proportional hazard models and competing risks regression models were formed to compare the outcomes of the groups. OS, DFS and GRFS were superior for 10/10 MUD (OS: HR 1.27, CI 1.10- 1.47, p=0.001, DFS: HR 1.17, CI 1.02-1.34, p=0.022, GRFS: HR 1.34, CI 1.19-1.50, p<0.001). Risk for aGVHD grade II-IV, aGVHD grade III-IV and cGVHD was higher in the PT-CY Haplo group compared to the 10/10 MUD group (aGVHD grade II-IV: HR 1.46, CI 1.25- 1.71, p<0.001; aGVHD grade III-IV: HR 1.74, CI 1.37- 2.20, p<0.001 and cGVHD: HR 1.30, CI 1.11-1.51, p=0.001). A lower incidence of relapse was observed in the PT-CY Haplo group (relapse: HR 0.83, CI 0.69-0.99, p=0.038). Unrelated 10/10 matched transplantation with ATG treatment leads to lower GvHD rates and improved survival rates when compared to PT-CY Haplo transplantation in Germany.

Identifiants

pubmed: 39368803
pii: 518081
doi: 10.1182/bloodadvances.2024013719
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Aysenur Arslan (A)

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany.

Svenja Labuhn (S)

University of Ulm, Ulm, Germany.

Elisa Sala (E)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Mark Ringhoffer (M)

Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany, Karlsruhe, Germany.

Johannes Schetelig (J)

Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany.

Thomas Schroeder (T)

University Hospital Essen, Essen, Germany.

Gesine Bug (G)

Goethe University Frankfurt, Frankfurt, Germany.

Georg-Nikolaus Franke (GN)

University of Leipzig, Leipzig, Germany.

Matthias Stelljes (M)

University Hospital Muenster, Muenster, Germany.

Peter Dreger (P)

University of Heidelberg, Heidelberg, Germany.

Robert Zeiser (R)

University Medical Center Freiburg, Freiburg, Germany.

Daniel Teschner (D)

University Hospital Würzburg, Würzburg, Germany.

Wolfgang Andreas Bethge (WA)

Medical Center University of Tuebingen, Tuebingen, Germany.

Matthias Eder (M)

Hannover Medical School, Hannover, Germany.

Matthias Edinger (M)

University Hospital Regensburg & Leibniz Institute for Immunotherapy, Regensburg, Germany.

Elisa Maria Amann (EM)

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany.

Christine Neuchel (C)

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany.

Amelie Schmid-Möglich (A)

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany.

Sandra Schmeller (S)

Institute of Statistics, Ulm University, Germany, Ulm, Germany.

Jan Beyersmann (J)

Institute of Statistics, University Ulm, Germany, Ulm, Germany.

Hubert Schrezenmeier (H)

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany.

Joannis Mytilineos (J)

German National Bone Marrow Donor Registry (ZKRD), Ulm, Germany.

Nicolaus Kröger (N)

University Medical Center Hamburg_Eppendorf, Hamburg, Germany.

Daniel Fuerst (D)

Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, Germany.

Classifications MeSH